These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

227 related items for PubMed ID: 29217781

  • 1. Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study.
    Ianotto JC, Chauveau A, Boyer-Perrard F, Gyan E, Laribi K, Cony-Makhoul P, Demory JL, de Renzis B, Dosquet C, Rey J, Roy L, Dupriez B, Knoops L, Legros L, Malou M, Hutin P, Ranta D, Benbrahim O, Ugo V, Lippert E, Kiladjian JJ.
    Haematologica; 2018 Mar; 103(3):438-446. PubMed ID: 29217781
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha.
    Stauffer Larsen T, Iversen KF, Hansen E, Mathiasen AB, Marcher C, Frederiksen M, Larsen H, Helleberg I, Riley CH, Bjerrum OW, Rønnov-Jessen D, Møller MB, de Stricker K, Vestergaard H, Hasselbalch HC.
    Leuk Res; 2013 Sep; 37(9):1041-5. PubMed ID: 23827351
    [Abstract] [Full Text] [Related]

  • 6. Myeloproliferative neoplasms treated with hydroxyurea, pegylated interferon alpha-2A or ruxolitinib: clinicohematologic responses, quality-of-life changes and safety in the real-world setting.
    Gill H, Leung GMK, Yim R, Lee P, Pang HH, Ip HW, Leung RYY, Li J, Panagiotou G, Ma ESK, Kwong YL.
    Hematology; 2020 Dec; 25(1):247-257. PubMed ID: 32567517
    [Abstract] [Full Text] [Related]

  • 7. Pegylated interferon for the treatment of early myelofibrosis: correlation of serial laboratory studies with response to therapy.
    O'Neill C, Siddiqi I, Brynes RK, Vergara-Lluri M, Moschiano E, O'Connell C.
    Ann Hematol; 2016 Apr; 95(5):733-8. PubMed ID: 26961933
    [Abstract] [Full Text] [Related]

  • 8. Experience with pegylated interferon α-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients.
    Gowin K, Thapaliya P, Samuelson J, Harrison C, Radia D, Andreasson B, Mascarenhas J, Rambaldi A, Barbui T, Rea CJ, Camoriano J, Gentry A, Kiladjian JJ, O'Connell C, Mesa R.
    Haematologica; 2012 Oct; 97(10):1570-3. PubMed ID: 22419578
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis.
    Rozovski U, Verstovsek S, Manshouri T, Dembitz V, Bozinovic K, Newberry K, Zhang Y, Bove JE, Pierce S, Kantarjian H, Estrov Z.
    Haematologica; 2017 Jan; 102(1):79-84. PubMed ID: 27686378
    [Abstract] [Full Text] [Related]

  • 11. A randomized, double-blind, placebo-controlled phase 3 study to assess efficacy and safety of ropeginterferon alfa-2b in patients with early/lower-risk primary myelofibrosis.
    Abu-Zeinah G, Qin A, Gill H, Komatsu N, Mascarenhas J, Shih WJ, Zagrijtschuk O, Sato T, Shimoda K, Silver RT, Mesa R.
    Ann Hematol; 2024 Sep; 103(9):3573-3583. PubMed ID: 39145781
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Recombinant interferon-α in myelofibrosis reduces bone marrow fibrosis, improves its morphology and is associated with clinical response.
    Pizzi M, Silver RT, Barel A, Orazi A.
    Mod Pathol; 2015 Oct; 28(10):1315-23. PubMed ID: 26271725
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Status and perspectives on chronic myeloproliferative neoplasm treatment].
    Ocias LF, Holmström MO, Riley CH, Andersen CL, Rønnov-Jessen D, Starklint J, Frederiksen M, Steffensen MS, Bjerrum OW, Farmer S, Mourits-Andersen T, Hasselbalch HC, Larsen TS.
    Ugeskr Laeger; 2015 May 04; 177(19):. PubMed ID: 25967090
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of pegylated interferon-α2a in patients with lamivudine-resistant HBeAg-positive chronic hepatitis B.
    Suh DJ, Lee HC, Byun KS, Cho M, Kweon YO, Tak WY, Chon CY, Koh KC, Lee YS.
    Antivir Ther; 2013 May 04; 18(6):765-73. PubMed ID: 23900457
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study.
    Jabbour E, Kantarjian H, Cortes J, Thomas D, Garcia-Manero G, Ferrajoli A, Faderl S, Richie MA, Beran M, Giles F, Verstovsek S.
    Cancer; 2007 Nov 01; 110(9):2012-8. PubMed ID: 17849460
    [Abstract] [Full Text] [Related]

  • 20. Pegylated interferon α2a induces complete remission of acute myeloid leukemia in a postessential thrombocythemia myelofibrosis permitting allogenic stem cell transplantation.
    Dagorne A, Douet-Guilbert N, Quintin-Roue I, Guillerm G, Couturier MA, Berthou C, Ianotto JC.
    Ann Hematol; 2013 Mar 01; 92(3):407-9. PubMed ID: 22941306
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.